GlassScriptPhysician profile
Jere M Johnson
NPI 1053355578
$3,007.15
in general payments reported to CMS, 2019-2025
28 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $311 · 2021: $285 · 2022: $331 · 2023: $337 · 2024: $401 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $777.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $489.33 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $338.72 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $207.98 | 2019-2025 | |
| Abbvie INC. | $171.55 | 2021-2025 | |
| Amgen INC. | $152.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $132.83 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $128.08 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $74.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $68.30 | 2019 | |
| Dexcom, INC. | $61.80 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $59.50 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $56.81 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $30.78 | 2023 | |
| Allergan, INC. | $29.70 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $27.24 | 2024 | Korlym |
| Amarin Pharma, INC. | $21.36 | 2019 | |
| Inspire Medical Systems, INC. | $21.23 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.62 | 2024 | Rexulti |
| Smith+Nephew, INC. | $18.44 | 2019 | |
| Sanofi Pasteur INC. | $17.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.70 | 2020 | |
| Phadia US INC. | $15.64 | 2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2019 | |
| Eisai INC. | $12.40 | 2020 | |
| Merck Sharp & Dohme LLC | $12.31 | 2020 | |
| Astellas Pharma US INC | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jere Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.